International Symposium on Immunotherapy and Immunodeficiency

November 19th – 20th, 2009
Lecture Hall,
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg, Germany
Dear Colleagues,

The immune system plays an important role during tumor development and progression. Cellular immune responses can be very powerful as seen in transplant rejection or graft versus host disease.

Therapeutic strategies utilizing tumor directed cellular immune responses are still experimental, whereas antibody based therapies are already standard of care in many tumor entities.

The Helmholtz Alliance on Immunotherapy of Cancer and the National Center for Tumor Diseases (NCT) Heidelberg have gathered many of the world wide leading experts on T lymphocyte physiology, immunodeficiency and lymphocyte based tumor therapy to reflect the current understanding of tumor immunology and discuss future therapeutic strategies.

We are happy to welcome you to our symposium on 19th – 20th November, 2009 in the beautiful city of Heidelberg to hear about the latest development and discuss critical issues of Immunotherapy and Immunodeficiency.
Directions

Location of the Lecture Hall of the German Cancer Research Center.

German Cancer Research Center, Lecture Hall
Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
8:15 **Welcome**  
*Wiestler, Otmar D.*

**Immunodeficiencies and gene therapy I**  
Chair: *Williams, David; von Kalle, Christof*

8:30 Clinical presentation, classification and genetics of common variable immunodeficiency  
*Peter, Hans-Hartmut*

9:00 Severe combined immunodeficiency: from molecular immunology to therapy  
*Cavazzana-Calvo, Marina*

9:30 Gene therapy for combined immunodeficiencies: from preclinical to clinical studies  
*Aiuti, Alessandro*

10:00 Update on gene therapies for SCID  
*Thrasher, Adrian*

10:30 Gene therapy for HIV: lessons learned and future decisions  
*Symonds, Geoff*

11:00 **Coffee**

**Immunodeficiencies and gene therapy II**  
Chair: *Cavazzana-Calvo, Marina; Peter, Hans-Hartmut*

11:30 Gene therapy of chronic granulomatous disease: lessons, chances and challenges  
*Grez, Manuel*

12:00 The clonal repertoire of the gene-modified human immune system  
*von Kalle, Christof*

12:20 Novel genetic defects of immunity – from molecular diagnosis to gene therapy  
*Klein, Christoph*

12:50 Hematopoietic cell gene therapy for X-linked adrenoleukodystrophy  
*Cartier, Nathalie*
Thursday, November 19th, 2009

13:20   Improving safety and efficacy of gene therapy by lentiviral vectors
        Naldini, Luigi

13:50   Lunch

**Mechanisms and targets in immunotherapy I**
Chair: Greenberg, Philip D.; Krammer, Peter

15:00   The utility of induced pluripotent stem cells in treatment of genetic blood diseases
        Williams, David

15:30   Molecular pathways in Notch-dependent acute lymphoblastic T cell leukemia
        von Boehmer, Harald

16:00   Regulatory T cells for immune tolerance and tumor immunity
        Sakaguchi, Shimon

16:30   Cancer immunoediting: mechanistic insights and therapeutic implications
        Schreiber, Robert

17:00   No escape
        Blankenstein, Thomas

17:20   Coffee

**Mechanisms and targets in immunotherapy II**
Chair: Allison, James; Jäger, Dirk

17:50   Tumor stroma and immune response
        Schreiber, Hans

18:20   Melanoma genetics – implications for tumor immunogenicity and immunotherapy
        Schadendorf, Dirk

18:40   Regulation of T cell responses against cancer
        Beckhove, Phillip

19:00   End
Friday, November 20th, 2009

**Pathways of therapeutic intervention**
Chair: Melief, Cornelis; Kirkwood, John

8:15 Resistance and sensitivity towards induction of apoptosis  
*Krammer, Peter*

8:35 The role of IL-15 in the life and death of lymphocytes: implications for cancer therapy and vaccine design  
*Waldmann, Thomas*

9:05 Immunological side effects of MAP kinase inhibitors for the recognition of tumor cells by cytotoxic T cells and NK cells  
*Falk, Christine*

9:25 Dendritic cell priming of high avidity allorestricted, peptide-specific T cells  
*Schendel, Dolores*

9:45 Acute hepatitis C – presentation and management  
*Manns, Michael*

10:05 **Coffee**

**T cell therapy**
Chair: Huber, Christoph; Meuer, Stefan

10:30 Adoptive transfer of natural Treg cells in stem cell transplantation  
*Edinger, Matthias*

11:00 Allogeneic immunotherapy of hematologic malignancies  
*Storb, Rainer*

11:30 New aspects of the GVL reaction  
*Kolb, Hans-Jochem*

11:50 New approaches for adoptive T cell transfer as treatment for hematological malignancies upon bone marrow transplantation  
*O’Reilly, Richard*

12:20 Development of effective T cell adoptive cancer immunotherapies  
*Robbins, Paul*
Friday, November 20th, 2009

12:50  T cell recognition of tumors: creating responses that can be effective in vivo  
Greenberg, Phillip

13:30  Lunch

Novel strategies in immunotherapy  
Chair: Schendel, Dolores; von Boehmer, Harald

14:30  Systemic therapy of melanoma  
Kirkwood, John

15:00  Targeting cancer stem cells  
Cebon, Jonathan

15:30  Overview of the cancer vaccine collaborative international clinical trials program  
Gnjatic, Sacha

16:00  Peptide-based vaccines for the immunotherapy of melanoma  
Romero, Pedro

16:30  Strategies for immunotherapy of established disease caused by high risk human papilloma viruses  
Melief, Cornelis

17:00  Coffee

Clinical intervention  
Chair: Schreiber, Robert; Storb, Rainer

17:30  Checkpoint blockade in immunotherapy  
Allison, James

18:00  Targeting dendritic cells in vivo – a novel approach to cure cancer  
Enk, Alexander

18:20  A novel paradigm for cancer  
Galon, Jerome

18:50  Characterization of anti-tumor immune responses: implication for treatment decisions  
Jäger, Dirk

19:10  End
Speakers and Chairpersons

Aiuti, Alessandro
MD, PhD, San Raffaele Telethon Institute for Gene Therapy, Milan; Italy

Allison, James
PhD, Institute for Immunology, Memorial Sloan-Kettering Cancer Center, New York; USA

Beckhove, Philipp
MD, Research Group Translational Immunology, German Cancer Research Center, Heidelberg; Germany

Blankenstein, Thomas
PhD, Department of Molecular Immunology and Gene Therapy, Max-Delbrück-Centrum, Berlin; Germany

Cartier, Nathalie
MD, PhD, INSERM, Hôpital Saint Vincent de Paul, Paris; France

Cavazzana-Calvo, Marina
MD, PhD, Department of Biotherapy at Necker Children’s Hospital, Paris; France

Cebon, Jonathan
MD, Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences – Cancer Vaccine Laboratory; Australia

Edinger, Matthias
MD, Department of Haematology and Oncology, University Hospital Regensburg; Germany

Enk, Alexander
MD, Department of Dermatology, University Hospital Heidelberg; Germany

Falk, Christine
PhD, Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and Institute for Immunology, University Heidelberg; Germany
Speakers and Chairpersons

Galon, Jerome  
PhD, Cordeliers Research Centre, INSERM Paris; France

Gnjatic, Sacha  
PhD, Ludwig Institute for Cancer Research at Memorial Sloan-Kettering Cancer Center, New York; USA

Greenberg, Philip D.  
MD, PhD, Fred Hutchinson Cancer Research Center, Seattle; USA

Grez, Manuel  
PhD, Georg-Speyer-Haus Frankfurt, Institute for Biomedical Research; Germany

Huber, Christoph  
MD, Department of Internal Medicine III, University Medical Center of the Johannes Gutenberg University Mainz; Germany

Jäger, Dirk  
MD, Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg; Germany

Kirkwood, John  
MD, Division of Hematology/Oncology, University of Pittsburgh, Medical Center; USA

Klein, Christoph  
MD, PhD, Department of Pediatric Hematology, Oncology, Hannover Medical School; Germany

Kolb, Hans-Jochem  
MD, Medizinische Klinik und Poliklinik III, Klinikum der Universität München-Großhadern; Germany

Krammer, Peter  
MD, Division Immunogenetics, German Cancer Research Center, Heidelberg; Germany
Speakers and Chairpersons

Manns, Michael  
MD, Department of Gastroenterology, Hepatology and Endocrinology, Centre for Internal Medicine, Hannover Medical School; Germany

Melief, Cornelis  
MD, PhD, Department of Immunohematology and Blood Transfusion, Leiden University; Netherlands

Meuer, Stefan  
MD, Institute for Immunology, University Heidelberg; Germany

Naldini, Luigi  
MD, PhD, San Raffaele Telethon Institute for Gene Therapy, Milan; Italy

O’Reilly, Richard  
MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York; USA

Peter, Hartmut  
MD, Department of Rheumatology and Clinical Immunology, University Hospital Freiburg; Germany

Robbins, Paul  
PhD, Tumor Immunology Section, National Cancer Institute, Bethesda; USA

Romero, Pedro  
MD, Ludwig Institute for Cancer Research, Lausanne Branch; Switzerland

Sakaguchi, Shimon  
MD, PhD, Institute for Frontier Medical Sciences, Kyoto University; Japan

Schadendorf, Dirk  
MD, Department of Dermatology, Venerology and Allergology, University of Essen, Medical Center; Germany
Speakers and Chairpersons

Schendel, Dolores
PhD, Institute of Molecular Immunology, Helmholtz-Zentrum München; Germany

Schreiber, Hans
MD, PhD, Department of Pathology, University of Chicago; USA

Schreiber, Robert
PhD, Department of Pathology & Immunology, Washington University – School of Medicine; USA

Storb, Rainer
MD, Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle; USA

Symonds, Geoff
PhD, Calimmune Inc., Sydney; Australia

Thrasher, Adrian
MD, PhD, University College London, Institute of Child Health; United Kingdom

von Boehmer, Harald
MD, PhD, Laboratory of Lymphocyte Biology, Dana Farber Cancer Institute, Boston; USA

von Kalle, Christof
MD, PhD, Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg; Germany

Waldmann, Thomas
MD, Cytokine Immunology and Immunotherapy Section, National Cancer Center, Bethesda; USA

Wiestler, Otmar D.
MD, Chairman and Scientific Director; German Cancer Research Center, Heidelberg; Germany

Williams, David
MD, Div. Hematology/Oncology, Children`s Hospital Boston; USA
Information and Contact

Date:
November 19th – 20th, 2009

Location:
Lecture Hall
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg, Germany

Information and Registration:
Dr. Astrid Beiglböck
Coordinator of the Medical Oncology at the National Center for Tumor Diseases (NCT) Heidelberg
Im Neuenheimer Feld 350
69120 Heidelberg, Germany
Phone: +49 (0) 6221 56-6904
Fax: +49 (0) 6221 56-7225
E-mail: astrid.beiglbueck@nct-heidelberg.de

Online-Registration:
http://immunotherapy.nct-meeting.de
Regular fee  250 €
Reduced rate  125 € (PhD Students, Students)